Bioventus Inc - Ordinary Shares - Class A
BVS
Get informed when a big investor buys or sells
+ FollowMarket Cap$956.94M
Close$
$25.83
85.9% upside
Current Fair Value
85.9% upsideUndervalued by 85.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $956.94 Million |
|---|---|
| Enterprise Value | $1.19 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.34 |
| Beta | 0.65 |
| Outstanding Shares | 67,869,148 |
Return
| Return on Equity | 23.86% |
|---|---|
| Return on Assets | 8.09% |
| Return on Invested Capital | 12.46% |
Valuation & Multiples
| P/E Ratio | 17.58 |
|---|---|
| PEG | 5.05 |
| Price to Sales | 1.74 |
| Price to Book Ratio | 3.47 |
| Enterprise Value to Revenue | 2.05 |
| Enterprise Value to EBIT | 18.35 |
| Enterprise Value to Net Income | 21 |
| Total Debt to Enterprise | 0.22 |
| Debt to Equity | 1.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.22
Average shareholder expectationRevenue Estimate
$155.44 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$0.17
Average shareholder expectationRevenue Estimate
$149.28 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 23.77% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 28.86%▼ 47.01% |
|---|---|
| Total Invested | $183.32M▼ 60.69% |
| Investors Holding | 56▼ 103.00% |
ESG Score
No data
About Bioventus Inc
700 employeesBioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations For Active Healing from Bioven...